190 related articles for article (PubMed ID: 19196068)
1. Creation of interferon-alpha8 mutants with amino acid substitutions against interferon-alpha receptor-2 binding sites using phage display system and evaluation of their biologic properties.
Yamamoto K; Taniai M; Torigoe K; Yamamoto S; Arai N; Suemoto Y; Yoshida K; Okura T; Mori T; Fujioka N; Tanimoto T; Miyata M; Ariyasu H; Ushio C; Fujii M; Ariyasu T; Ikeda M; Ohta T; Kurimoto M; Fukuda S
J Interferon Cytokine Res; 2009 Mar; 29(3):161-70. PubMed ID: 19196068
[TBL] [Abstract][Full Text] [Related]
2. The combination of IFN-alpha2 and IFN-alpha8 exhibits synergistic antiproliferative activity on renal cell carcinoma (RCC) cell lines through increased binding affinity for IFNAR-2.
Tanimoto T; Yamamoto S; Taniai M; Taniguchi M; Ariyasu H; Ushio C; Aga M; Mukai Y; Tsutsumi Y; Ariyasu T; Ohta T; Fukuda S
J Interferon Cytokine Res; 2007 Jun; 27(6):517-23. PubMed ID: 17572016
[TBL] [Abstract][Full Text] [Related]
3. Amino acid substitutions in loop BC and helix C affect antigenic properties of helix D in hybrid IFN-alpha21a/alpha2c molecules.
Schmeisser H; Hu R; Kontsek P; Bekisz J; Zoon K
J Interferon Cytokine Res; 2002 Apr; 22(4):463-72. PubMed ID: 12034029
[TBL] [Abstract][Full Text] [Related]
4. Mutation of the IFNAR-1 receptor binding site of human IFN-alpha2 generates type I IFN competitive antagonists.
Pan M; Kalie E; Scaglione BJ; Raveche ES; Schreiber G; Langer JA
Biochemistry; 2008 Nov; 47(46):12018-27. PubMed ID: 18937499
[TBL] [Abstract][Full Text] [Related]
5. Domains of interaction between alpha interferon and its receptor components.
Uzé G; Di Marco S; Mouchel-Vielh E; Monneron D; Bandu MT; Horisberger MA; Dorques A; Lutfalla G; Mogensen KE
J Mol Biol; 1994 Oct; 243(2):245-57. PubMed ID: 7932753
[TBL] [Abstract][Full Text] [Related]
6. Mutational and structural analysis of the binding interface between type I interferons and their receptor Ifnar2.
Piehler J; Schreiber G
J Mol Biol; 1999 Nov; 294(1):223-37. PubMed ID: 10556041
[TBL] [Abstract][Full Text] [Related]
7. Human IFN-alpha protein engineering: the amino acid residues at positions 86 and 90 are important for antiproliferative activity.
Hu R; Bekisz J; Schmeisser H; McPhie P; Zoon K
J Immunol; 2001 Aug; 167(3):1482-9. PubMed ID: 11466368
[TBL] [Abstract][Full Text] [Related]
8. Activity of hybrid type I interferons in cells lacking Tyk2: a common region of IFN-alpha 8 induces a response, but IFN-alpha2/8 hybrids can behave like IFN-beta.
Platis D; Foster GR
J Interferon Cytokine Res; 2003 Nov; 23(11):655-66. PubMed ID: 14651780
[TBL] [Abstract][Full Text] [Related]
9. A structural basis for interferon-alpha-receptor interactions.
Kumaran J; Wei L; Kotra LP; Fish EN
FASEB J; 2007 Oct; 21(12):3288-96. PubMed ID: 17517919
[TBL] [Abstract][Full Text] [Related]
10. Biologic activities of natural and synthetic type I interferons.
Pfeffer LM
Semin Oncol; 1997 Jun; 24(3 Suppl 9):S9-63-S9-69. PubMed ID: 9208874
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a single amino acid substitution at position 79 of human IFN-α2b in interferon-receptor assembly and activity.
Talebi S; Saeedinia A; Zeinoddini M; Ahmadpour F; Sadeghizadeh M
Prep Biochem Biotechnol; 2019; 49(8):735-743. PubMed ID: 31135267
[TBL] [Abstract][Full Text] [Related]
12. Functional significance of globotriaosyl ceramide in interferon-alpha(2)/type 1 interferon receptor-mediated antiviral activity.
Khine AA; Lingwood CA
J Cell Physiol; 2000 Jan; 182(1):97-108. PubMed ID: 10567921
[TBL] [Abstract][Full Text] [Related]
13. Determination of residues involved in ligand binding and signal transmission in the human IFN-alpha receptor 2.
Chuntharapai A; Gibbs V; Lu J; Ow A; Marsters S; Ashkenazi A; De Vos A; Jin Kim K
J Immunol; 1999 Jul; 163(2):766-73. PubMed ID: 10395669
[TBL] [Abstract][Full Text] [Related]
14. A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities.
Ozes ON; Reiter Z; Klein S; Blatt LM; Taylor MW
J Interferon Res; 1992 Feb; 12(1):55-9. PubMed ID: 1573283
[TBL] [Abstract][Full Text] [Related]
15. Identification of critical residues in bovine IFNAR-1 responsible for interferon binding.
Cutrone EC; Langer JA
J Biol Chem; 2001 May; 276(20):17140-8. PubMed ID: 11278538
[TBL] [Abstract][Full Text] [Related]
16. The carboxyterminal domains of human IFN-alpha2 and IFN-alpha8 are antigenically homologous.
Vancová I; Kontseková E; Mucha V; Kontsek P
J Interferon Cytokine Res; 2000 May; 20(5):455-61. PubMed ID: 10841073
[TBL] [Abstract][Full Text] [Related]
17. Three-dimensional models of interferon-alpha subtypes IFN-con1, IFN-alpha8, andIFN-alpha1 derived from the crystal structure of IFN-alpha2b.
Walter MR
Semin Oncol; 1997 Jun; 24(3 Suppl 9):S9-52-S9-62. PubMed ID: 9208873
[TBL] [Abstract][Full Text] [Related]
18. Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta.
Jaitin DA; Roisman LC; Jaks E; Gavutis M; Piehler J; Van der Heyden J; Uze G; Schreiber G
Mol Cell Biol; 2006 Mar; 26(5):1888-97. PubMed ID: 16479007
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the antiviral activities of natural IFN-alpha preparations and their subtype compositions.
Yanai Y; Sanou O; Kayano T; Ariyasu H; Yamamoto K; Yamauchi H; Ikegami H; Kurimoto M
J Interferon Cytokine Res; 2001 Oct; 21(10):835-41. PubMed ID: 11710996
[TBL] [Abstract][Full Text] [Related]
20. Biologic and binding activities of IFN-alpha subtypes in ACHN human renal cell carcinoma cells and Daudi Burkitt's lymphoma cells.
Yamaoka T; Kojima S; Ichi S; Kashiwazaki Y; Koide T; Sokawa Y
J Interferon Cytokine Res; 1999 Dec; 19(12):1343-9. PubMed ID: 10638703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
